Carbagen

Availability of Carbagen (Carbamazepine)

200mg and 400mg


Latest Supply Status

Mylan continues to experience supply constraints with all strengths of Carbagen (Carbamazepine), which includes Carbagen 200mg and Carbagen 400mg Tablets, Carbagen 200mg Prolonged-Release (PR) Tablets and Carbagen 400mg Prolonged-Release (PR) Tablets.

Whilst there is currently good availability of Carbagen 200mg Tablets, please see details of other strengths:

  • Carbagen 400mg

Carbagen 400mg is not currently available and we anticipate normal stock levels will resume in Q2 2020.

  • Carbagen 200mg PR and 400mg PR

Carbagen 200mg PR and 400mg PR are not currently available.

 We are reviewing future supply forecasting regularly and working closely with the manufacturing team to stay informed of anticipated shipments.

We will continue to proactively provide updates on our website regarding any changes in stock availability for all strengths and are maintaining regular contact with health authorities to provide frequent updates on supply.

Information for Patients

Mylan is unable to make any specific treatment recommendations to patients. Patients should speak to their healthcare provider to discuss treatment options according to their health needs and their relevant clinical history.

Reporting of side effects

If you get any side effects talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at http://www.mhra.gov.uk/yellowcard. By reporting side effects, you can help provide more information on the safety of this medicine. You should also report any side effects to Mylan UK Pharmacovigilance on +44 (0)800 121 8267 or ukpharmacovigilance@mylan.com.

About Carbagen

Carbagen is indicated for the treatment of:

  • Epilepsy
    • generalised tonic-clonic
    • partial seizures
  • For the paroxysmal pain of trigeminal neuralgia.
  • For the prophylaxis of manic or hypomanic phases of manic-depressive psychosis in patients unresponsive or with contraindications to lithium therapy.

Resources

Carbagen 200mg Prolonged-Release Tablets – Patient Information Leaflet and SmPC

Carbagen 400mg Prolonged-Release Tablets – Patient Information Leaflet and SmPC

Carbagen 200mg Tablets – Patient Information Leaflet and SmPC

Carbagen 400mg Tablets – Patient Information Leaflet and SmPC

Contact Information

Mylan Medical Information team can be contacted via the Mylan switch board on +44 (0)1707 853000 (Option 1)



CAR-2019-007
DOP: DECEMBER 2019